Groups | Â | ||||
---|---|---|---|---|---|
Tumors | 1 -ve control | 2 (0.2Â g/kg TH) | 3 (1.0Â g/kg TH) | 4 (2.0Â g/kg TH) | S.E |
Total No of tumors developed. | 35 | 16 | 20 | 15 | Â |
No. of Caspase-9 positive tumors (% expression) | 16 (45.7%) | 13 (81.3%) | 14 (70.0%) | 11 (73.3%) | 1.20 |
No. of Apaf-1 positive tumors (% expression) | 15 (42.9%) | 15 (93.8%) | 16 (80.0%) | 11 (73.3%) | 1.28 |
No. of FASLG positive tumors (% expression) | 13 (37.1%) | 0 | 0 | 0 | 3.75 |
No. of FADD positive tumors (% expression) | 12 (34.3%) | 0 | 0 | 0 | 3.64 |
No. of Bcl-xL positive tumors (% expression) | 28 (80.0%) | 9 (56.3%) | 10 (50.0%) | 10 (66.7%) | 5.29 |
No. of ESR1 positive tumors (% expression) | 26 (74.28%) | 8 (50%) | 11 (55%) | 9 (60%) | 4.86 |